<DOC>
	<DOC>NCT01355367</DOC>
	<brief_summary>This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8 week double blind treatment phase of Study 13176.</brief_summary>
	<brief_title>High Dose BAYA1040 CR: a Long Term Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Patients who complete the 8 week double blind treatment phase of Study 13176 and for whom the test drug is tolerable Patients with expected difficulties for the continuous 1 year follow up</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>BAYA1040 CR</keyword>
	<keyword>Nifedipine</keyword>
	<keyword>Essential hypertension</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase III</keyword>
	<keyword>Extension study</keyword>
</DOC>